Apeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China

Stock News

09/09

Apeloa Pharmaceutical Co.,Ltd. (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing Authorization Approval Notice from China's National Medical Products Administration for Cefditoren Pivoxil.

The approval marks a significant milestone, officially granting the company the right to sell this active pharmaceutical ingredient within the domestic Chinese market. This development is set to broaden the company's product pipeline and strengthen its API business segment.

Strategically, the approval aligns with Apeloa's corporate objective to refine and enhance its API operations. By expanding its portfolio with this newly approved product, the company reinforces its commitment to business development and expects this to yield positive impacts on its future growth trajectory.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1155717358"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155717358\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155717358?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 17:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155717358","market":"fut","top_or_hot":-1,"title":"Apeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China","media":"Stock News","content":"<p><b>Apeloa Pharmaceutical Co.,Ltd.</b> (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing Authorization Approval Notice from China's National Medical Products Administration for Cefditoren Pivoxil.<br><br>The approval marks a significant milestone, officially granting the company the right to sell this active pharmaceutical ingredient within the domestic Chinese market. This development is set to broaden the company's product pipeline and strengthen its API business segment.<br><br>Strategically, the approval aligns with Apeloa's corporate objective to refine and enhance its API operations. By expanding its portfolio with this newly approved product, the company reinforces its commitment to business development and expects this to yield positive impacts on its future growth trajectory.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-09-09 17:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>Apeloa Pharmaceutical Co.,Ltd.</b> (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing Authorization Approval Notice from China's National Medical Products Administration for Cefditoren Pivoxil.<br><br>The approval marks a significant milestone, officially granting the company the right to sell this active pharmaceutical ingredient within the domestic Chinese market. This development is set to broaden the company's product pipeline and strengthen its API business segment.<br><br>Strategically, the approval aligns with Apeloa's corporate objective to refine and enhance its API operations. By expanding its portfolio with this newly approved product, the company reinforces its commitment to business development and expects this to yield positive impacts on its future growth trajectory.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"","article_id":"1155717358","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155717358","pubTimestamp":1788947414,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Apeloa Pharmaceutical Co.,Ltd. (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0060":"抗癌","IPOS":"Renaissance International IPO ETF","BK0188":"融资融券","BK0239":"医药制造","000739":"普洛药业"},"translate_title":"Apeloa Pharmaceutical 在中国获得头孢地妥仑吡沃酯原料药的监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"000739":1},"content_text":"Apeloa Pharmaceutical Co.,Ltd. (SZSE: 000739) has announced that its wholly-owned subsidiary, Zhejiang Apeloa D&B Pharmaceutical Co., Ltd., recently received the Chemical Drug API Marketing Authorization Approval Notice from China's National Medical Products Administration for Cefditoren Pivoxil.The approval marks a significant milestone, officially granting the company the right to sell this active pharmaceutical ingredient within the domestic Chinese market. This development is set to broaden the company's product pipeline and strengthen its API business segment.Strategically, the approval aligns with Apeloa's corporate objective to refine and enhance its API operations. By expanding its portfolio with this newly approved product, the company reinforces its commitment to business development and expects this to yield positive impacts on its future growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}